Invention Grant
- Patent Title: PTEFB inhibiting macrocyclic compounds
-
Application No.: US17558390Application Date: 2021-12-21
-
Publication No.: US11691986B2Publication Date: 2023-07-04
- Inventor: Ulrich Lücking , Daniel Hog , Clara Christ , Ulrike Sack , Franziska Siegel , Philip Lienau , Nicolas Werbeck
- Applicant: Bayer Aktiengesellschaft , Bayer Pharma Aktiengesellschaft
- Applicant Address: DE Leverkusen
- Assignee: BAYER AKTIENGESELLSCHAFT,BAYER PHARMA AKTIENGESELLSCHAFT
- Current Assignee: BAYER AKTIENGESELLSCHAFT,BAYER PHARMA AKTIENGESELLSCHAFT
- Current Assignee Address: DE Leverkusen; DE Berlin
- Agency: Wilson Sonsini Goodrich & Rosati
- Priority: EP 163419 2017.03.28
- The original application number of the division: US16497578
- Main IPC: C07D213/61
- IPC: C07D213/61 ; C07D498/18 ; C07D239/30 ; C07D498/08

Abstract:
The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
Public/Granted literature
- US20220267353A1 PTEFB INHIBITING MACROCYCLIC COMPOUNDS Public/Granted day:2022-08-25
Information query